Pieris will be responsible for advancing its preclinical lead candidate, PRS-060, into initial Phase I clinical trials in 2017
AstraZeneca boosted its early-stage respiratory medicine pipeline by signing a deal with Pieris Pharmaceuticals to develop novel inhaled drugs that could fight asthma in new ways.
Pieris will get upfront and near-term milestone payments of $57.5 million and up to $2.1 billion if the experimental drugs go on to become commercially successful.
Pieris will be responsible for advancing its preclinical lead candidate, PRS-060, into initial Phase I clinical trials in 2017, the two companies said.
- Advertisement -
Comments are closed.